StockMarketWire.com - Hutchison China MediTech said it had initiated an international clinical trial of its drug to treat patients with relapsed or refractory lymphoma.

The primary outcomes of the clinical trial measures were safety and tolerability. Secondary outcomes include pharmacokinetic (PK) measurements and preliminary efficacy such as objective response rate (ORR), the company said.

The first patient in the trial was dosed on 26 Sept, 2019 in the US.









At 8:17am: [LON:HCM] Hutchison China Meditech Ltd share price was +5.5p at 300.5p



Story provided by StockMarketWire.com